胎儿结构异常的分子尸检:多学科团队方法的诊断与临床效用
该回顾性服务评估在2021年1月至12月间,对围产期死亡伴结构异常且疑似遗传病因的123例病例进行多学科团队(MDT)评估,其中84例推荐遗传学检测、64例接受检测,29例获得30个诊断,总体诊断率为24%(29/123),接受检测者诊断率为45%(29/64);尸检在79%病例中提供可指导临床的表型数据。结论认为基因组检测是尸检的临床有用补充而非替代,MDT有助于评估和规划随访。
要点
- 总体诊断率24%(29/123),接受遗传学检测者诊断率45%(29/64)。
- 尸检在79%的病例中提供可指导临床的表型数据。
- MDT推荐遗传学评估84例,其中64例接受检测。
核心结论
- 基因组检测是围产期死亡伴结构异常病例尸检的临床有用补充而非替代。
- MDT方法有助于评估病例并规划适当随访。
- 快速全基因组测序或面板不可知分析最适合异质性表现。
- 该广泛方法可扩展产前表型知识并检测新疾病基因,应作为未来研究优先事项。
研究设计与样本
- 回顾性服务评估,纳入2021年1月至12月期间接受围产期MDT评估的所有围产期死亡伴结构异常且疑似遗传病因的病例。
- 共123例在2021年MDT会议上讨论,所有病例接受完整或部分尸检及至少染色体微阵列分析。
- 从患者病历中收集人口学特征、表型、基因型、MDT建议、诊断、结局及尸检分析和遗传学检测数据的影响。
主要发现
- 共123例在MDT会议上讨论,84例推荐遗传学评估,64例接受。
- 在26个无关家庭的29例中做出30个诊断。
- 总体诊断率为24%(29/123),接受遗传学检测的疑似遗传诊断病例诊断率为45%(29/64)。
- 尸检在79%的病例中提供可指导临床的表型数据。
- 遗传诊断使准确的再发风险咨询和适当随访成为可能,包括对遗传性疾病患者进行产前检测和植入前诊断。
临床怎么用
- MDT方法有助于评估病例并规划适当随访。
- 快速全基因组测序或面板不可知分析最适合异质性表现。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In the West Midlands regional genetics service, cases of perinatal death with a possible genetic diagnosis are evaluated by the perinatal pathology genetic multidisciplinary team (MDT). The MDT assesses autopsy findings and suggests appropriate genomic assessment. The objective of this retrospective service evaluation was to determine the clinical utility of the MDT in assessing perinatal deaths associated with structural anomaly. This is the first evaluation since the introduction of whole-genome and whole-exome sequencing in routine clinical care. METHODS: This was a retrospective service evaluation including all cases of perinatal death with an associated structural anomaly and suspected genetic etiology that underwent perinatal MDT assessment between January and December 2021. All cases received a full or partial postmortem examination and at least a chromosomal microarray analysis. Demographic characteristics, phenotype, genotype, MDT recommendations, diagnoses, outcomes and impact of postmortem analysis and genetic testing data were collected from patient case notes. RESULTS: Overall, 123 cases were discussed at the MDT meetings in 2021. Genetic evaluation was recommended in 84 cases and accepted in 64 cases. A range of genetic tests were requested according to indication and availability. Thirty diagnoses were made in 29 cases from 26 unrelated families. The diagnostic yield was 24% (29/123) in all cases or 45% (29/64) in cases with a suspected genetic diagnosis who underwent genetic testing. Postmortem examination provided clinically actionable phenotypic data in 79% of cases. A genetic diagnosis enabled accurate recurrence risk counseling and provision of appropriate follow-up, including prenatal testing and preimplantation diagnosis for patients with inherited conditions. CONCLUSIONS: Genomic testing was a clinically useful addition to (but not a substitute for) postmortem examination in cases of perinatal death associated with structural anomaly. The MDT approach helped assess cases and plan appropriate follow-up. Expedited whole-genome sequencing or panel-agnostic analysis were most appropriate for heterogeneous presentations. This broad approach can also expand knowledge of prenatal phenotypes and detect novel disease genes, and should be a priority in future research. © 2024 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Wall E, Petley E, Mone F, et al. Molecular autopsy for fetal structural anomaly: diagnostic and clinical utility of multidisciplinary team approach. Ultrasound Obstet Gynecol. 2024. PMID: 38517166. doi:10.1002/uog.27647
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。